Biosimilar epoetins

Nephrology Dialysis Transplantation

Volumn 24, Issue 5, 2009, Pages 1698-1699

  MacDougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR EPOIETIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOETIN ZETA; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RETACRIT; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; CLINICAL TRIAL; DRUG COST; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SUBSTITUTION; HUMAN; LETTER; PRIORITY JOURNAL; PURE RED CELL ANEMIA;

ANEMIA; BIOPHARMACEUTICS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; HEALTH CARE COSTS; HEMATINICS; HUMANS; RED-CELL APLASIA, PURE; RISK FACTORS;

EID: 65249173920     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp111     Document Type: Letter

References (12)

1. Covic A, Cannata-Andia J, Cancarini G et al. Biosimilars and bio-pharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23: 3731-3737
2. Krivoshiev S, Todorov VV, Manitius J et al. Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24: 1407-1415
3. Kaufman JS, Reda DJ, Fye CL et al. Department of Veterans Affairs Cooperative Study GrouponErythropoietininHemodialysis Patients. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-583
4. Bock HA, Hirt-Minkowski P, Brünisholz M et al. for the Swiss EFIXNES Trial Investigators. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialy-sis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008; 23: 301-308
5. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406
6. Krause RS. Anaphylaxis. Medscape updated 6 October 2008. http://emedicine.medscape.com/article/756150-overview (31 January 2009, date last accessed)
7. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues - Guidance on Similar Medicinal Products containing Recombinant Erythropoietins CHMP/94526/05, 2006
8. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1385-1387
9. Macdougall IC, Casadevall N, Froissart M et al. Treatment of ery-thropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist. J Am Soc Nephrol 2007; 18: 80A
10. Tolman C, Duja S, Richardson D et al. Four cases of pure red cell aplasia secondary to epoetin beta, with strong temporal relationships. Nephrol Dial Transplant 2004; 19: 2133-2136
11. Jacob A, Sandhu K, Nicholas J et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant 2006; 21: 2963-2965
12. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action.Exp Hematol 2008; 36: 1573-1584